EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial

Chiara Herzog iD, Allison Jones, Iona Evans, Daniel Reisel, Adeola Olaitan, Konstantinos Doufekas, Nicola MacDonald, Angelique Flöter Rådestad, Kristina Gemzell-Danielsson, Michal Zikan, David Cibula, Lukáš Dostálek und 9 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Chiara Herzog und 20 weiteren Autor:innen. Beteiligte Einrichtung: European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria. Hauptthemen laut MEDLINE: DNA Methylation, Ovarian Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Analysis of cell‐free DNA methylation (cfDNAme), alone or combined with CA125, could help to detect ovarian cancers earlier and may reduce mortality. We assessed cfDNAme in regions of ZNF154, C2CD4D and WNT6 via targeted bisulfite sequencing in diagnostic and early detection (preceding diagnosis) settings. Diagnostic samples were obtained via prospective blood collection in cell‐free DNA tubes in a convenience series of patients with a pelvic mass. Early detection samples were matched case‐control samples derived from the UK Familial Ovarian Cancer Screening Study (UKFOCSS). In the diagnostic set (n cases = 27, n controls = 41), the specificity of cfDNAme was 97.6% (95% CI: 87.1%‐99.9%). High‐risk cancers were detected with a sensitivity of 80% (56.3%‐94.3%). Combination of cfDNAme and CA125 resulted in a sensitivity of 94.4% (72.7%‐99.9%) for high‐risk cancers. Despite technical issues in the early detection set (n cases = 29, n controls = 29), the specificity of cfDNAme was 100% (88.1%‐100.0%). We detected 27.3% (6.0%‐61.0%) of high‐risk cases with relatively lower genomic DNA (gDNA) contamination. The sensitivity rose to 33.3% (7.5%‐70.1%) in samples taken

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationOvarian NeoplasmsHumansFemaleCase-Control StudiesProspective StudiesEarly Detection of CancerBiomarkers, TumorCA-125 AntigenKruppel-Like Transcription Factors

Stichwörter der Autor:innen

cell-free DNAdiagnosismethylationovarian cancer

Substanzen

Biomarkers, TumorCA-125 AntigenZNF154 protein, humanKruppel-Like Transcription Factors

Autor:innen und Institutionen

  • European Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria.
  • Research Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria.
  • Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
  • Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Department of Gynecology and Obstetrics, Charles University in Prague, First Faculty of Medicine and Hospital, Na Bulovce, Czech Republic.
  • Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, Prague and, General University Hospital, Prague, Czech Republic.

ORCID-Profile: Chiara Herzog, Usha Menon, Martin Widschwendter

Förderung

  • European Research Council
  • Medical Research Council

Zitieren

APA

Herzog, C., Jones, A., Evans, I., Reisel, D., Olaitan, A., Doufekas, K., MacDonald, N., Rådestad, A. F., Gemzell-Danielsson, K., Zikan, M., Cibula, D., Dostálek, L., Paprotka, T., Leimbach, A., Schmitt, M., Ryan, A., Gentry-Maharaj, A., Apostolidou, S., Rosenthal, A. N., …, & Widschwendter, M. (2024). Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial. International Journal of Cancer. https://doi.org/10.1002/ijc.34757

Vancouver

Herzog C, Jones A, Evans I, Reisel D, Olaitan A, Doufekas K, et al. Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial. International Journal of Cancer. 2024. doi:10.1002/ijc.34757

BibTeX
@article{Herzog2024,
  author = {Herzog, Chiara and Jones, Allison and Evans, Iona and Reisel, Daniel and Olaitan, Adeola and Doufekas, Konstantinos and MacDonald, Nicola and Rådestad, Angelique Flöter and Gemzell-Danielsson, Kristina and Zikan, Michal and Cibula, David and Dostálek, Lukáš and Paprotka, Tobias and Leimbach, Andreas and Schmitt, Markus and Ryan, Andy and Gentry-Maharaj, Aleksandra and Apostolidou, Sophia and Rosenthal, Adam N and Menon, Usha and Widschwendter, Martin},
  title = {Plasma cell‐free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case‐control study and an ovarian cancer screening trial},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34757}
}
Kostenlos starten →